The utility of the CxBladder in detecting recurrent tumours in patients undergoing intravesical Bacillus Calmette-Guerin (BCG) therapy or Mitomycin C (MMC) therapy for bladder cancer.
Not Applicable
Completed
- Conditions
- Bladder cancertransitional cell carcinomaurothelial carcinomaCancer - Bladder
- Registration Number
- ACTRN12616001180404
- Lead Sponsor
- Pacific Edge Diagnostics Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Men and women between 18 and 85 years undergoing BCG or Mitomycin C (MMC) therapy for urothelial carcinoma or DMSO/heparin therapy for painful bladder syndrome at Concord Hospital.
The study invites patients undergoing DMSO/heparin therapy as a control group - The Cxbladder results from these patients are compared against those for the BCG or Mitomycin C (MMC) therapy patients.
Exclusion Criteria
Patients declining involvement in the study and patients with obvious active urinary tract infections.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method